Reactions 1704, p209 - 2 Jun 2018 troponin-T level. His unspecified statin treatment was discontinued but his condition worsened along with development of myalgia and dyspnoea. A repeat laboratory investigation revealed further increase in the creatine Various toxicities: 9 case reports phosphokinase and liver enzyme levels. His CRP level was also In a retrospective review study, nine patients (7 men and elevated. On the fourth day of hospitalisation, a muscle biopsy 2 women) aged 19 76 years were described who developed showed necrotic muscle fibres with infiltration by meningoencephalitis, limbic encephalitis, myositis with macrophages and T-lymphocytes. An echocardiogram cardiac complications including cardiac arrhythmia, revealed regional wall motion abnormality with an estimated polyradiculitis, ocular myasthenic syndrome, reactivated left ventricular ejection fraction of 50%. His pembrolizumab myasthenia, rash or cranial polyneuropathy during treatment treatment was discontinued. He was then treated with bilevel with ipilimumab, nivolumab or pembrolizumab [routes not positive airway pressure support, but his respiratory condition stated; not all dosages stated]. Two patients eventually died continued to deteriorate. Therefore, myositis and cardiac due to cardiac arrhythmia or myasthenic syndrome and septic complications as possible immune-related adverse events due shock. to pembrolizumab were suspected. He started receiving Patient 1: A 68-year-old
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera